Noise induced hearing loss

Summary

Noise induced hearing loss (MONDO:0013098) is a disease with 9 cohort genes (3 GWAS associations across 4 studies) and 21 clinical trials. Top therapeutic interventions include methylprednisolone, zonisamide, and disufenton sodium.

At a glance

• Cohort genes: 9
• GWAS associations: 3
• ClinVar variants: 1
• Clinical trials: 21

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	noise induced hearing loss
Mondo ID	MONDO:0013098
EFO	EFO:1001254
MeSH	D006317
NCIT	C34664
SNOMED CT	73415002
UMLS	C0018781
MedGen	5455
Is cancer (heuristic)	no

Also known as: hearing loss, noise-induced, susceptibility to · NIHL · noise-induced hearing loss

Data availability: 1 ClinVar variant · 3 GWAS associations (4 studies).

Disease family

Classification path: disease › human disease › disease by body system or component › auditory system disorder › hearing disorder › hearing loss disorder › noise induced hearing loss

Related subtypes (10): Johanson-Blizzard syndrome, nonsyndromic genetic hearing loss, sudden hearing loss disorder, sensorineural hearing loss disorder, conductive hearing loss disorder, central hearing loss, X-linked deafness, auditory neuropathy, hearing loss, mixed conductive-sensorineural, drug-induced hearing loss

Genetics & variants

GWAS landscape

3 GWAS associations across 4 studies. Top hits map to 3 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs7598759	5e-07	NCL	?	12.75
rs35075890	1e-06	AUTS2	G	3.17
rs10081191	2e-06	PTPRN2	A	1.99

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90081540	Backman JD	2021	16,069	13,961	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90085526	Backman JD	2021	16,069	13,961	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST011920	Niu Y	2020	89	0	Genome-wide association study identifies 7q11.22 and 7q36.3 associated with noise-induced hearing loss among Chinese population.
GCST003006	Grondin Y	2015	19	0	Genetic Polymorphisms Associated with Hearing Threshold Shift in Subjects during First Encounter with Occupational Impulse Noise.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	3

MAF distribution

Bucket	Variants
common (>=0.05)	3
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	0

Functional consequences

Consequence	Count
intron_variant	3

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs7598759	2	231457245	C>A,G,T	0.05	intron_variant	NCL	5e-07	Tier 4: intronic/intergenic
rs35075890	7	70713244	A>C,G,T	0.05	intron_variant	AUTS2	1e-06	Tier 4: intronic/intergenic
rs10081191	7	158530114	A>C,G,T	0.05	intron_variant	PTPRN2	2e-06	Tier 4: intronic/intergenic

ClinVar germline variants

1 retrieved; paginated sample, class counts are floors:

1 benign

ClinVar	Variant (HGVS)	Gene	Classification	Review
132651	NM_000219.6(KCNE1):c.112A>G (p.Ser38Gly)	KCNE1	Benign	criteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 7 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
AUTS2	Orphanet:352490	Autism spectrum disorder due to AUTS2 deficiency
AUTS2	Orphanet:641372	B-lymphoblastic leukemia/lymphoma with t(7;9)(q11.2;p13.2)
DYNC2I1	Orphanet:474	Jeune syndrome
DYNC2I1	Orphanet:93271	Short rib-polydactyly syndrome, Verma-Naumoff type
KCNE1	Orphanet:101016	Romano-Ward syndrome
KCNE1	Orphanet:334	Hereditary atrial fibrillation
KCNE1	Orphanet:90647	Jervell and Lange-Nielsen syndrome

Cohort genes → proteins

9 cohort genes, 9 distinct canonical proteins.

Evidence partition

Subset	Genes
gwas_only	8
multi_evidence	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
VIPR2	HGNC:12695	ENSG00000106018	P41587	Vasoactive intestinal polypeptide receptor 2	gwas
AUTS2	HGNC:14262	ENSG00000158321	Q8WXX7	Autism susceptibility gene 2 protein	gwas
GALNT17	HGNC:16347	ENSG00000185274	Q6IS24	Polypeptide N-acetylgalactosaminyltransferase 17	gwas
DYNC2I1	HGNC:21862	ENSG00000126870	Q8WVS4	Cytoplasmic dynein 2 intermediate chain 1	gwas
NCAPG2	HGNC:21904	ENSG00000146918	Q86XI2	Condensin-2 complex subunit G2	gwas
ESYT2	HGNC:22211	ENSG00000117868	A0FGR8	Extended synaptotagmin-2	gwas
KCNE1	HGNC:6240	ENSG00000180509	P15382	Potassium voltage-gated channel subfamily E member 1	clinvar
NUCLEOLIN	HGNC:7667	ENSG00000115053	P19338	Nucleolin	gwas
PTPRN2	HGNC:9677	ENSG00000155093	Q92932	Receptor-type tyrosine-protein phosphatase N2	gwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
VIPR2	Vasoactive intestinal polypeptide receptor 2	G protein-coupled receptor activated by the neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (ADCYAP1/PACAP).
AUTS2	Autism susceptibility gene 2 protein	Component of a Polycomb group (PcG) multiprotein PRC1-like complex, a complex class required to maintain the transcriptionally repressive state of many genes, including Hox genes, throughout development.
GALNT17	Polypeptide N-acetylgalactosaminyltransferase 17	May catalyze the initial reaction in O-linked oligosaccharide biosynthesis, the transfer of an N-acetyl-D-galactosamine residue to a serine or threonine residue on the protein receptor.
DYNC2I1	Cytoplasmic dynein 2 intermediate chain 1	Acts as one of several non-catalytic accessory components of the cytoplasmic dynein 2 complex (dynein-2 complex), a motor protein complex that drives the movement of cargos along microtubules within cilia and flagella in concert with the i…
NCAPG2	Condensin-2 complex subunit G2	Regulatory subunit of the condensin-2 complex, a complex which establishes mitotic chromosome architecture and is involved in physical rigidity of the chromatid axis.
ESYT2	Extended synaptotagmin-2	Tethers the endoplasmic reticulum to the cell membrane and promotes the formation of appositions between the endoplasmic reticulum and the cell membrane.
KCNE1	Potassium voltage-gated channel subfamily E member 1	Ancillary protein that functions as a regulatory subunit of the voltage-gated potassium (Kv) channel complex composed of pore-forming and potassium-conducting alpha subunits and of regulatory beta subunits.
NUCLEOLIN	Nucleolin	Nucleolin is the major nucleolar protein of growing eukaryotic cells.
PTPRN2	Receptor-type tyrosine-protein phosphatase N2	Plays a role in vesicle-mediated secretory processes.

Protein-family classification

Druggable: 3 · Difficult: 1 · Unknown: 5 · Druggable fraction: 0.33

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Ion channel	1	12.4×	0.256
Phosphatase	1	9.3×	0.256
GPCR	1	2.7×	0.519
Scaffold/PPI	1	1.9×	0.519
Other/Unknown	5	1.0×	0.641

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
VIPR2	GPCR	yes		GPCR_2_secretin-like, GPCR_2_VIP_rcpt, GPCR_2_extracellular_dom
AUTS2	Other/Unknown	no		AUTS2
GALNT17	Other/Unknown	no		Ricin_B_lectin, Glyco_trans_2-like, Nucleotide-diphossugar_trans
DYNC2I1	Scaffold/PPI	no		WD40_rpt, WD40/YVTN_repeat-like_dom_sf, WD40_repeat_dom_sf
NCAPG2	Other/Unknown	no		ARM-like, ARM-type_fold, Condensin2_G2
ESYT2	Other/Unknown	no		C2_dom, SMP_LBD, C2_domain_sf
KCNE1	Ion channel	yes		K_chnl_KCNE, KCNE1
NUCLEOLIN	Other/Unknown	no		RRM_dom, RRM_euk-type, Nucleotide-bd_a/b_plait_sf
PTPRN2	Phosphatase	yes	3.1.3.48	PTP_cat, Tyr_Pase_dom, Tyr_Pase_cat

Expression context

Cohort genes with no expression data: 0.

9 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	9
unknown	0

Top tissues across cohort

Tissue	Cohort genes
cortical plate	2
ganglionic eminence	2
ventricular zone	2
apex of heart	1
heart left ventricle	1
mucosa of stomach	1
tibia	1
cerebellar vermis	1
dorsal root ganglion	1
trigeminal ganglion	1
right uterine tube	1
sperm	1
sural nerve	1
oocyte	1
secondary oocyte	1
calcaneal tendon	1
layer of synovial tissue	1
saphenous vein	1
blood	1
leukocyte	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
VIPR2	169	broad	marker	mucosa of stomach, apex of heart, heart left ventricle
AUTS2	292	ubiquitous	marker	cortical plate, tibia, ganglionic eminence
GALNT17	199	broad	marker	trigeminal ganglion, dorsal root ganglion, cerebellar vermis
DYNC2I1	269	ubiquitous	marker	sural nerve, right uterine tube, sperm
NCAPG2	217	ubiquitous	marker	ventricular zone, secondary oocyte, oocyte
ESYT2	261	ubiquitous	marker	layer of synovial tissue, calcaneal tendon, saphenous vein
KCNE1	121	broad	marker	blood, monocyte, leukocyte
NUCLEOLIN	165	ubiquitous	marker	ventricular zone, ganglionic eminence, cortical plate
PTPRN2	254	broad	marker	lateral nuclear group of thalamus, middle temporal gyrus, lateral globus pallidus

Protein interactions among cohort

Intra-cohort edges: 4.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
NUCLEOLIN	5,960
NCAPG2	1,831
AUTS2	1,700
ESYT2	1,684
PTPRN2	1,491
VIPR2	1,488
KCNE1	1,005
DYNC2I1	955
GALNT17	852

Intra-cohort edges

A	B	Sources
AUTS2	GALNT17	string_interaction
DYNC2I1	ESYT2	string_interaction
DYNC2I1	NCAPG2	string_interaction
ESYT2	NCAPG2	string_interaction

Structural data

PDB: 7 · AlphaFold-only: 2 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
KCNE1	P15382	5
DYNC2I1	Q8WVS4	4
ESYT2	A0FGR8	4
NUCLEOLIN	P19338	4
VIPR2	P41587	3
PTPRN2	Q92932	3
NCAPG2	Q86XI2	1

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
GALNT17	Q6IS24	90.68
AUTS2	Q8WXX7	41.89

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 19. Enrichment computed across 9 evidence-associated genes (9 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 9 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Glycosphingolipid transport	1	158.6×	0.050	ESYT2
Assembly and Release of Dengue Virus Virions	1	158.6×	0.050	NUCLEOLIN
Phase 3 - rapid repolarisation	1	126.9×	0.050	KCNE1
Phase 2 - plateau phase	1	84.6×	0.056	KCNE1
Respiratory syncytial virus (RSV) attachment and entry	1	55.2×	0.068	NUCLEOLIN
Glucagon-type ligand receptors	1	38.5×	0.080	VIPR2
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known	1	33.4×	0.080	AUTS2
Intraflagellar transport	1	22.3×	0.101	DYNC2I1
O-linked glycosylation of mucins	1	20.5×	0.101	GALNT17
Condensation of Prophase Chromosomes	1	17.4×	0.103	NCAPG2
Transcriptional regulation by RUNX1	1	16.3×	0.103	AUTS2
Cardiac conduction	1	12.1×	0.126	KCNE1
Muscle contraction	1	8.6×	0.158	KCNE1
G alpha (s) signalling events	1	8.1×	0.158	VIPR2
Major pathway of rRNA processing in the nucleolus and cytosol	1	6.9×	0.173	NUCLEOLIN
Neutrophil degranulation	1	2.6×	0.375	PTPRN2
RNA Polymerase II Transcription	1	2.5×	0.375	AUTS2
Gene expression (Transcription)	1	2.0×	0.428	AUTS2
Generic Transcription Pathway	1	1.7×	0.460	AUTS2

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 9 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
vestibular nucleus development	1	936.2×	0.023	KCNE1
secretory granule organization	1	374.5×	0.023	KCNE1
regulation of secretion	1	312.1×	0.023	PTPRN2
obsolete endoplasmic reticulum-plasma membrane tethering	1	312.1×	0.023	ESYT2
negative regulation of protein targeting to membrane	1	312.1×	0.023	KCNE1
negative regulation of delayed rectifier potassium channel activity	1	312.1×	0.023	KCNE1
positive regulation of chromosome condensation	1	234.1×	0.023	NCAPG2
regulation of potassium ion transport	1	208.1×	0.023	KCNE1
cardiac muscle cell contraction	1	187.2×	0.023	KCNE1
membrane repolarization during action potential	1	187.2×	0.023	KCNE1
membrane repolarization during cardiac muscle cell action potential	1	187.2×	0.023	KCNE1
dendrite extension	1	187.2×	0.023	AUTS2
membrane repolarization during ventricular cardiac muscle cell action potential	1	187.2×	0.023	KCNE1
positive regulation of chromosome separation	1	187.2×	0.023	NCAPG2
epithelial cell maturation	1	170.2×	0.023	KCNE1
positive regulation of transcription of nucleolar large rRNA by RNA polymerase I	1	170.2×	0.023	NUCLEOLIN
insulin secretion involved in cellular response to glucose stimulus	1	144.0×	0.023	PTPRN2
positive regulation of chromosome segregation	1	144.0×	0.023	NCAPG2
membrane repolarization	1	144.0×	0.023	KCNE1
intraciliary retrograde transport	1	124.8×	0.023	DYNC2I1
potassium ion export across plasma membrane	1	117.0×	0.023	KCNE1
inner cell mass cell proliferation	1	110.1×	0.023	NCAPG2
ventricular cardiac muscle cell action potential	1	110.1×	0.023	KCNE1
positive regulation of potassium ion transmembrane transport	1	110.1×	0.023	KCNE1
chromosome condensation	1	93.6×	0.025	NCAPG2
regulation of ventricular cardiac muscle cell membrane repolarization	1	93.6×	0.025	KCNE1
neurotransmitter secretion	1	78.0×	0.028	PTPRN2
cardiac muscle cell action potential involved in contraction	1	78.0×	0.028	KCNE1
positive regulation of Rac protein signal transduction	1	72.0×	0.030	AUTS2
regulation of potassium ion transmembrane transport	1	69.3×	0.030	KCNE1

Therapeutics

Drugs indicated for this disease

0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Methionine	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Vatiquinone.

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 2 · Phased (≥1): 2 · Undrugged: 7

Druggability breadth: 4 of 9 evidence-associated genes (44%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
KCNE1	AMBRISENTAN

Top cohort targets by molecule count

Symbol	Molecules	Max phase
KCNE1	14	4
VIPR2	2	3
AUTS2	0	0
GALNT17	0	0
DYNC2I1	0	0
NCAPG2	0	0
ESYT2	0	0
NUCLEOLIN	0	0
PTPRN2	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
AMBRISENTAN	4	KCNE1
DULOXETINE	4	KCNE1
PALONOSETRON	4	KCNE1
DARUNAVIR	4	KCNE1
DARIFENACIN	4	KCNE1
TOLTERODINE	4	KCNE1
SOLIFENACIN	4	KCNE1
EVEROLIMUS	4	KCNE1
RALTEGRAVIR	4	KCNE1
MARAVIROC	4	KCNE1
ALVIMOPAN	4	KCNE1
NEBIVOLOL	4	KCNE1
SUNITINIB	4	KCNE1
NELFINAVIR	4	KCNE1
AVIPTADIL	3	VIPR2
MK-0893	2	VIPR2

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
KCNE1	117	Functional:63, Binding:47, ADMET:6, Toxicity:1
VIPR2	27	Functional:14, Binding:13
NUCLEOLIN	8	Binding:8
ESYT2	1	Binding:1

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
PTPRN2	3.1.3.48	protein-tyrosine-phosphatase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
KCNE1	117

Pharmacogenomics

Cohort genes with a PharmGKB record: 9; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

16 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
AMBRISENTAN	4	KCNE1
DULOXETINE	4	KCNE1
PALONOSETRON	4	KCNE1
DARUNAVIR	4	KCNE1
DARIFENACIN	4	KCNE1
TOLTERODINE	4	KCNE1
SOLIFENACIN	4	KCNE1
EVEROLIMUS	4	KCNE1
RALTEGRAVIR	4	KCNE1
MARAVIROC	4	KCNE1
ALVIMOPAN	4	KCNE1
NEBIVOLOL	4	KCNE1
SUNITINIB	4	KCNE1
NELFINAVIR	4	KCNE1
AVIPTADIL	3	VIPR2
MK-0893	2	VIPR2

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	KCNE1
B	Phased (≥1) drug, not yet approved	1	VIPR2
C	Druggable family + PDB, no drug	1	PTPRN2
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	6	AUTS2, GALNT17, DYNC2I1, NCAPG2, ESYT2, NUCLEOLIN

Undrugged target profiles

7 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
AUTS2	0	—
GALNT17	0	—
DYNC2I1	0	—
NCAPG2	0	—
ESYT2	1	—
NUCLEOLIN	8	—
PTPRN2	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 21.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	9
PHASE2	5
PHASE1	3
PHASE1/PHASE2	2
PHASE3	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02903355	PHASE3	TERMINATED	Phase 3 Clinical Trial: D-methionine to Reduce Noise-Induced Hearing Loss (NIHL)
NCT07304024	PHASE1/PHASE2	RECRUITING	A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound
NCT00808470	PHASE2	COMPLETED	Micronutrients to Prevent Noise-induced Hearing Loss
NCT02049073	PHASE1/PHASE2	WITHDRAWN	Prevention of Noise-induced Hearing Loss
NCT02257983	PHASE2	COMPLETED	Protective Effects of EPI-743 on Noise-Induced Hearing Loss
NCT02779192	PHASE2	UNKNOWN	A Phase 2b Study of SPI-1005 to Prevent Acute Noise Induced Hearing Loss
NCT04120116	PHASE2	COMPLETED	FX-322 in Adults With Stable Sensorineural Hearing Loss
NCT05086276	PHASE2	COMPLETED	FX-322 in Adults With Acquired Sensorineural Hearing Loss
NCT02259595	PHASE1	COMPLETED	Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC
NCT04601909	PHASE1	COMPLETED	FX-322 in Adults With Age-Related Sensorineural Hearing Loss
NCT04629664	PHASE1	COMPLETED	FX-322 in Adults With Severe Sensorineural Hearing Loss
NCT07472023	EARLY_PHASE1	ENROLLING_BY_INVITATION	Regenerative Medicine and Stem Cell-Based Interventions for Inner Ear Trauma, Tinnitus, and Sensorineural Hearing Loss
NCT06729632	Not specified	RECRUITING	Non-Invasive System to Deliver Therapeutic Hypothermia for Protection Against Noise-Induced Hearing Loss
NCT07513077	Not specified	RECRUITING	Prevention of Noise-Induced Hearing Loss in Primary Education
NCT07534098	Not specified	NOT_YET_RECRUITING	Intervention for Hearing Health Among Native Americans
NCT01454895	Not specified	COMPLETED	Test of a Web-based Intervention to Promote Hearing Protector Use
NCT01727492	Not specified	UNKNOWN	Prevention of Noise-induced Damage by Use of Antioxidants
NCT02472821	Not specified	COMPLETED	Test of Hearing Health Education Programs for Farm and Rural Youth
NCT04183361	Not specified	UNKNOWN	ABR Characteristics and Salivary Cortisone Concentration in Noise-exposed Workers
NCT05511753	Not specified	UNKNOWN	The Effect of Acupuncture on Patients With Noise-induced Hearing Loss
NCT05636488	Not specified	UNKNOWN	Determination of the Effects of Noise Level in the Operating Room

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
METHYLPREDNISOLONE	4	1
ZONISAMIDE	4	1
DISUFENTON SODIUM	3	1
EBSELEN	3	1
VATIQUINONE	3	1
CHEMBL1234268	0	1